Augment Injectable Bone Graft: Phase III ongoing

In its 3Q11 earnings, BioMimetic said it proposed to expand enrollment to 300 patients in a North American

Read the full 181 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE